Skip to content

Study · Non-randomized trial · n = 6 · 1995

2 results

Desmopressin (DDAVP) acts on platelets to generate platelet microparticles and enhanced procoagulant activity.

Horstman LL, Valle-Riestra BJ, Jy W, Wang F, Mao W, Ahn YS

Thrombosis research1 Jul 1995Cited by 33 (Europe PMC)

PMID7676403 (opens in a new tab)DOI10.1016/0049-3848(95)00102-w (opens in a new tab)PepBankPUB-07676403
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialMechanism

    In six patients, platelet microparticle formation increased after DDAVP infusion, with a smaller effect than in vitro.

    In plain wordsIn patients, platelet microparticle formation increased after DDAVP infusion compared with before infusion.

    Peptide
    Desmopressin
    Outcome
    IncreasePlatelet microparticle formation
    Study

    n = 6

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated · infusionAs given in this study (human).

    Source sentences

    Summary
    The assays were also performed on six patients prior to and at one hour after infusion of DDAVP, and similar but lesser effects were observed.
    2 context sentences
    Summary · context
    A mean increase of 2-3 fold was observed in both PMP and procoagulant activity.
    Summary · context
    We examined the effect of DDAVP on platelet microparticle (PMP) formation and procoagulant activity in vitro using platelets from normal volunteers and in vivo in six patients receiving DDAVP therapy.
  2. 02HumanNon-randomized trialMechanism

    In six patients, procoagulant activity increased after DDAVP infusion, with a smaller effect than in vitro.

    In plain wordsIn patients, clot-promoting activity increased after DDAVP infusion compared with before infusion.

    Peptide
    Desmopressin
    Outcome
    IncreaseProcoagulant activity
    Study

    n = 6

    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated · infusionAs given in this study (human).

    Source sentences

    Summary
    The assays were also performed on six patients prior to and at one hour after infusion of DDAVP, and similar but lesser effects were observed.
    2 context sentences
    Summary · context
    A mean increase of 2-3 fold was observed in both PMP and procoagulant activity.
    Summary · context
    We examined the effect of DDAVP on platelet microparticle (PMP) formation and procoagulant activity in vitro using platelets from normal volunteers and in vivo in six patients receiving DDAVP therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.